ZLAB
Zai Lab Ltd

1,221
Mkt Cap
$1.93B
Volume
723,818.00
52W High
$44.34
52W Low
$17.25
PE Ratio
-8.90
ZLAB Fundamentals
Price
$17.34
Prev Close
$17.77
Open
$17.68
50D MA
$24.03
Beta
1.17
Avg. Volume
973,856.68
EPS (Annual)
-$2.60
P/B
2.52
Rev/Employee
$213,583.80
Loading...
Loading...
News
all
press releases
Zai Lab (NASDAQ:ZLAB) Hits New 1-Year Low - Should You Sell?
Zai Lab (NASDAQ:ZLAB) Sets New 1-Year Low - Here's What Happened...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the dosing of the first participant in a global Phase 1/1b clinical trial evaluating the safety, tolerability, pharmacokinetics, and...
Business Wire·8d ago
News Placeholder
Zai Lab Announces Updates to Chinas National Reimbursement Drug List
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the following medicines and indications have been renewed in the 2025 National Reimbursement Drug List (NRDL) released by Chinas...
Business Wire·9d ago
News Placeholder
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of "Moderate Buy" by Brokerages
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) has earned an average rating of "Moderate Buy" from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. One...
MarketBeat·18d ago
News Placeholder
Zai Lab (NASDAQ:ZLAB) Sees Strong Trading Volume - Here's Why
Zai Lab (NASDAQ:ZLAB) Sees Strong Trading Volume - Here's What Happened...
MarketBeat·18d ago
News Placeholder
Zai Lab (NASDAQ:ZLAB) Issues Earnings Results
Zai Lab (NASDAQ:ZLAB - Get Free Report) announced its earnings results on Thursday. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by...
MarketBeat·1mo ago
News Placeholder
Zai Lab (NASDAQ:ZLAB) Sets New 52-Week Low on Disappointing Earnings
Zai Lab (NASDAQ:ZLAB) Hits New 52-Week Low Following Weak Earnings...
MarketBeat·1mo ago
News Placeholder
Zai Lab Announces Participation in Investor Conferences in November and December 2025
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Companys senior management team will participate in the following investor conferences in November and December 2025...
Business Wire·2mo ago
News Placeholder
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced updated data from the global Phase 1 clinical trial of zocilurtatug pelitecan (zoci), formerly known as ZL-1310, (NCT06179069) demonstrating...
Business Wire·2mo ago
News Placeholder
The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners
The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners The Institute for Follicular...
PR Newswire·2mo ago
<
1
2
...
>

Latest ZLAB News

View

Advertisement|Remove ads.

Advertisement|Remove ads.